Dating and social networking app Grindr, which is geared for the gay, bisexual, transgender, and queer (LGBTQ) community is in legal hot water for allegedly selling the private information, including HIV status, of "potentially thousands" of users to third parties without consent.
Advertisement
The study’s primary end point was objective response rate determined through blinded independent central review.
Dr. Ronan Kelly describes his trial on nivolumab with relatlimab for the treatment of resectable esophageal/GEJ cancer.
Dr. Gulam A. Manji discusses CXCR4 and PD-1 inhibitors and how research has shown a potential benefit of the combination.
Dr. Gulam A. Manji discusses the ARC-8 study on quemliclustat plus gemcitabine/nab-paclitaxel with and without zimberelimab.
A bill to improve access to care and outcomes for some dialysis patients was introduced in the House of Representatives.
Good heart health is linked to less cognitive decline among middle-aged Black women.
The addition of dostarlimab to platinum chemotherapy is cost effective and significantly improves QOL.
Research has begun to question recommendations to restrict potassium with CKD to manage hyperkalemia.
DocWire Content Partners
Gain insights from The CardioNerds, a group of cardiology experts who aim to democratize cardiovascular education.
Fundamentals, core concepts, and important management approaches in the field of hematology and oncology
Dr. Chadi Nabhan, a renowned voice in hematology and oncology, tackles a multitude of relevant health care topics.
Drs. Rohit Gosain and Rahul Gosain discuss practice-changing data and standards of oncology care.
Dr. Hady Lichaa is an interventional cardiologist specializing in complex coronary interventions.
Review important issues in the rheumatology space, including lupus, rheumatoid arthritis, and more, from Dr. Maheswaranathan.
Powered by DocWire News
The Latest From GI Oncology Now
The study’s primary end point was objective response rate determined through blinded independent central review.
Dr. Ronan Kelly describes his trial on nivolumab with relatlimab for the treatment of resectable esophageal/GEJ cancer.
Dr. Gulam A. Manji discusses CXCR4 and PD-1 inhibitors and how research has shown a potential benefit of the combination.
Dr. Gulam A. Manji discusses the ARC-8 study on quemliclustat plus gemcitabine/nab-paclitaxel with and without zimberelimab.
Surgical resection with curative intent is the primary therapy for gastric cancer, yet the 5-year survival rate is just 20%.
This marks the first FDA approval of a radioactive drug for patients 12 years or older with SSTER-positive GEP-NETs.
The Latest From Heme Today
Etavopivat was safe and increased hemoglobin, decreased hemolysis, and improved red blood cells in patients with SCD.
Dr. Vadivelan shared her study on pituitary and pancreatic iron deposition in patients with SCD at the 2024 ASPHO Conference.
Stuart Orkin, MD, has been named as one of Time’s 100 Most Influential People of 2024 for his work in hemoglobin research.
The study compared health care resource use and costs of pediatric patients with SCD compared with matched controls.
Intravenous iron was safe and effective in pediatric patients with iron deficiency anemia and inflammatory bowel disease.
Delaying treatment for SAA until genetic testing for IBMFS may be detrimental in patients with negative workup and history.
